Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes

Tuesday, October 9, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, October 8 Innovation in the pharma industry isnot at a standstill: it has changed direction. Where once small moleculeresearch provided the mainstay of companies' profits, biological drugs arenow making their presence felt. While the range of genomic sciences waits tomake its impact, biologicals are providing the current focus for noveldiscovery. Yet biologicals do not behave like small molecules; the rules fortheir development are different and they are often little understood.

The 2007 update to the Scrip Report 'How Drugs are Developed' responds tothese changes. First published four years ago, and revised in 2005, theReport aims to inform all those involved with pharmaceutical R&D how each ofthe necessary disciplines fit together to take a new medicine from discoveryto market launch.

Sections of the Report that previously focused on small molecules havenow been expanded to describe the corresponding processes for biologicals. Toincrease its value even further, the 2007 update features two brand newchapters. The first deals with project management: the fundamentals ofmanaging multidisciplinary teams and the ways in which the role is changingto encompass external as well as internal interfaces. The second concerns thegrowing interest in translational research; the ways in which laboratoryconcepts can be converted into medical advances.

The 234-page update retains all the Report's original sections, givingreaders a firm grounding in all the stages of drug development from drugtarget hunting, lead generation and optimisation through to preclinicalresearch, clinical evaluation and post-marketing surveillance. It also givesa step-by-step account of the various stages of preparing for drugdevelopment and the processes involved in making regulatory submissions. TheReport also includes over 60 figures all of which serve to aid the reader'sunderstanding of the issues discussed.

When the first edition of the Report was published in 2003, the impact ofsequencing the human genome was just being felt throughout the industry. Now,in 2007, it is apparent that while providing promise for the future, therewill be no 'quick fix' for the industry and it must pursue an ever widerrange of opportunities to achieve its goals. The result is a networkedindustry without historical parallel.

Scrip Reports publishes an extensive range of pharmaceutical therapeuticmarket reports, detailed analyses of the pharmaceutical market for specificgeographic areas, in-depth profiles of companies operating in the industry,financial and statistical analyses, directories and other strategic reportson the healthcare sector.Visit http://www.scripreports.com. For further press details contact Jenefer Trevena Managing Editor Scrip Publishing Tel: +44-(0)20-7017-6989 Email: jenefer.trevena@informa.com. To purchase How Drugs are Developed 2007, contact: Andrew Maitland Sales Manager Tel: +44-(0)20-7017-6859 Email: andrew.maitland@informa.com quote code JR20004P.

SOURCE Scrip Reports

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store